Dr. Abbey presented the at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human study to evaluate the safety and efficacy of intravitreal injection of EYP-1901, a sustained-release tyrosine kinase inhibitor that shows great promise in reducing the treatment burden for patients with .
ARVO is the largest and most respected eye and vision research organization in the world, and its members include nearly 10,000 researchers from over 75 countries.
Texas Retina Associates is currently involved in the Phase 2 trial — DAVIO 2 — and was one of the top enrolling centers for the study. DAVIO 2 is evaluating best corrected visual acuity 6 months after an EYP-1901 injection compared to a control group receiving an aflibercept injection.
Clickto watch a video of Dr. Abbey discussing the Phase 1 DAVIO study results.
Dr. Abbey cares for patients in ourand offices, and also serves as our Director of Research for Dallas. You can learn more about him .